中文版 | English
Title

Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials

Author
Corresponding AuthorChen, Qiuling; Yuan, Jie; Geng, Qingshan
Publication Years
2022-09-30
DOI
Source Title
EISSN
1663-9812
Volume13
Abstract
Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0.38-0.62); 0.810-0.84 (0.69-0.98)] and any stroke [0.56 (0.42-0.75)] at the expense of increased risk of major bleeding [1.79 (1.34-2.39); 2.08-2.38 (1.56-3.28)], whereas, clopidogrel monotherapy reduced the risk of any stroke, major bleeding, and intracranial bleeding. On subgroup analysis, compared with aspirin alone, addition of prasugrel resulted in lower MACE [0.72 (0.60-0.86)], MI [0.48 (0.38-0.62)], and stent thrombosis [0.29 (0.09-0.91)], whereas, addition of rivaroxaban 2.5 mg resulted in lower risk of MACE [0.72 (0.60-0.87)], cardiac death [0.71 (0.52-0.98)] and any stroke [0.65 (0.45-0.95)], but not reduced MI. Both prasugrel and rivaroxaban 2.5 mg increased major bleeding [1.79 (1.34-2.39); 1.72 (1.33-2.22)]. Clopidogrel monotherapy was associated with lower MACE [0.72 (0.58-0.90)], any stroke [0.42 (0.24-0.73)], and major bleeding [0.62 (0.40-0.96)]. Adding prasugrel or ticagrelor led to a reduced incidence of MI and prasugrel was also found to reduce the risk of MACE and stent thrombosis in CCS patients with low risk of bleeding after PCI. Clopidogrel monotherapy has advantage in reducing MACE, stroke, and major bleeding events in CCS patients at high risk of bleeding after PCI.
Keywords
URL[Source Record]
Indexed By
Language
English
SUSTech Authorship
Corresponding
Funding Project
[JCYJ20210324113614038] ; [SZXK003] ; [SZXK059] ; [SZSM201412012]
WOS Research Area
Pharmacology & Pharmacy
WOS Subject
Pharmacology & Pharmacy
WOS Accession No
WOS:000868662500001
Publisher
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:1
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/406518
DepartmentShenzhen People's Hospital
Affiliation
1.Jinan Univ, Shenzhen Peoples Hosp, Dept Cardiol, Clin Med Coll 2, Shenzhen, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Cardiovasc Minimally Invas Med Engn Technol Res &, Shenzhen Key Med Disciplin SZXK003, Shenzhen, Guangdong, Peoples R China
3.Guangzhou Univ Chinese Med Futian, Inst Shenzhen Hosp, Shenzhen, Peoples R China
4.Shenzhen Peoples Hosp, Dept Pharm, Shenzhen, Guangdong, Peoples R China
5.Shenzhen Peoples Hosp, Dept Geriatr, Shenzhen, Guangdong, Peoples R China
First Author AffilicationShenzhen People's Hospital
Corresponding Author AffilicationShenzhen People's Hospital
Recommended Citation
GB/T 7714
Lin, Yaowang,Cai, Zhigang,Dong, Shaohong,et al. Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials[J]. FRONTIERS IN PHARMACOLOGY,2022,13.
APA
Lin, Yaowang.,Cai, Zhigang.,Dong, Shaohong.,Liu, Huadong.,Pang, Xinli.,...&Geng, Qingshan.(2022).Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials.FRONTIERS IN PHARMACOLOGY,13.
MLA
Lin, Yaowang,et al."Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials".FRONTIERS IN PHARMACOLOGY 13(2022).
Files in This Item:
There are no files associated with this item.
Related Services
Fulltext link
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Lin, Yaowang]'s Articles
[Cai, Zhigang]'s Articles
[Dong, Shaohong]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Lin, Yaowang]'s Articles
[Cai, Zhigang]'s Articles
[Dong, Shaohong]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Lin, Yaowang]'s Articles
[Cai, Zhigang]'s Articles
[Dong, Shaohong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.